Drug recall · August 10, 2022
Matzim LA recall
Why: Failed Dissolution Specifications: below specification limits for dissolution.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30.
- Lots / codes
Lot 1411593A, Exp 09/22
- Quantity
- 8022 bottles
- Company
- Teva Pharmaceuticals USA Inc, Parsippany, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- July 21, 2022 · Voluntary: Firm initiated
- Classified
- August 4, 2022
- Reported
- August 10, 2022
- Ended
- April 18, 2023
- How notified
- N/A
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Matzim
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.